ANIP
Income statement / Annual
Last year (2023), ANI Pharmaceuticals, Inc.'s total revenue was $486.82 M,
an increase of 53.87% from the previous year.
In 2023, ANI Pharmaceuticals, Inc.'s net income was $18.78 M.
See ANI Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$486.82 M
|
$316.39 M
|
$216.14 M
|
$208.48 M
|
$206.55 M
|
$201.58 M
|
$176.84 M
|
$128.62 M
|
$76.32 M
|
$55.97 M
|
| Cost of Revenue |
$181.51 M |
$138.79 M |
$100.61 M |
$87.16 M |
$63.15 M |
$73.02 M |
$79.03 M |
$48.78 M |
$12.69 M |
$11.47 M |
| Gross Profit |
$305.30 M |
$177.60 M |
$115.53 M |
$121.32 M |
$143.39 M |
$128.55 M |
$97.81 M |
$79.84 M |
$63.63 M |
$44.50 M |
| Gross Profit Ratio |
0.63 |
0.56 |
0.53 |
0.58 |
0.69 |
0.64 |
0.55 |
0.62 |
0.83 |
0.8 |
| Research and Development
Expenses |
$34.29 M
|
$22.32 M
|
$11.37 M
|
$16.00 M
|
$19.81 M
|
$15.39 M
|
$9.07 M
|
$2.91 M
|
$2.87 M
|
$2.68 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$44.06 M
|
$31.58 M
|
$27.83 M
|
$21.16 M
|
$17.94 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$161.70 M
|
$124.04 M
|
$84.29 M
|
$64.99 M
|
$55.84 M
|
$44.06 M
|
$31.58 M
|
$27.83 M
|
$21.16 M
|
$17.94 M
|
| Other Expenses |
$0.00 |
$56.97 M |
$48.03 M |
$55.90 M |
$51.32 M |
-$550,000.00 |
$55,000.00 |
-$74,000.00 |
$41,000.00 |
$160,000.00 |
| Operating Expenses |
$195.98 M |
$203.33 M |
$143.70 M |
$136.89 M |
$126.97 M |
$93.19 M |
$68.58 M |
$53.08 M |
$30.93 M |
$24.49 M |
| Cost And Expenses |
$439.85 M |
$342.12 M |
$244.31 M |
$224.05 M |
$190.12 M |
$166.22 M |
$147.61 M |
$101.86 M |
$43.62 M |
$35.96 M |
| Interest Income |
$0.00 |
$28.05 M |
$11.92 M |
$9.45 M |
$12.97 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$26.94 M |
$28.05 M |
$11.92 M |
$9.45 M |
$12.97 M |
$14.76 M |
$12.04 M |
$11.33 M |
$11.01 M |
$787,000.00 |
| Depreciation &
Amortization |
$59.79 M
|
$56.97 M
|
$47.25 M
|
$44.64 M
|
$44.61 M
|
$33.74 M
|
$27.93 M
|
$22.34 M
|
$6.90 M
|
$3.88 M
|
| EBITDA |
$109.32 M
|
$48.07 M
|
-$1.68 M
|
$29.07 M
|
$60.74 M
|
$69.10 M
|
$57.16 M
|
$56.31 M
|
$39.64 M
|
$24.04 M
|
| EBITDA Ratio |
0.22 |
0.1 |
0.07 |
0.14 |
0.29 |
0.34 |
0.32 |
0.38 |
0.52 |
0.43 |
| Operating Income Ratio
|
0.1
|
-0.08
|
-0.15
|
-0.08
|
0.08
|
0.18
|
0.16
|
0.16
|
0.43
|
0.36
|
| Total Other
Income/Expenses Net |
-$27.10 M
|
-$27.38 M
|
-$16.27 M
|
-$9.95 M
|
-$13.19 M
|
-$15.31 M
|
-$11.98 M
|
-$11.40 M
|
-$10.97 M
|
-$627,000.00
|
| Income Before Tax |
$19.87 M |
-$62.67 M |
-$56.06 M |
-$25.96 M |
$3.16 M |
$20.05 M |
$16.35 M |
$8.68 M |
$21.73 M |
$19.38 M |
| Income Before Tax Ratio
|
0.04
|
-0.2
|
-0.26
|
-0.12
|
0.02
|
0.1
|
0.09
|
0.07
|
0.28
|
0.35
|
| Income Tax Expense |
$1.09 M |
-$14.77 M |
-$13.46 M |
-$3.41 M |
-$2.94 M |
$4.56 M |
$17.43 M |
$4.74 M |
$6.36 M |
-$9.37 M |
| Net Income |
$18.78 M |
-$47.90 M |
-$42.60 M |
-$22.55 M |
$6.09 M |
$15.49 M |
-$1.08 M |
$3.93 M |
$15.38 M |
$28.75 M |
| Net Income Ratio |
0.04 |
-0.15 |
-0.2 |
-0.11 |
0.03 |
0.08 |
-0.01 |
0.03 |
0.2 |
0.51 |
| EPS |
0.95 |
-2.95 |
-3.38 |
-1.88 |
0.51 |
1.33 |
-0.0932 |
0.34 |
1.34 |
2.61 |
| EPS Diluted |
0.94 |
-2.95 |
-3.38 |
-1.88 |
0.5 |
1.32 |
-0.0932 |
0.34 |
1.32 |
2.59 |
| Weighted Average Shares
Out |
$18.00 M
|
$16.26 M
|
$12.60 M
|
$11.96 M
|
$11.84 M
|
$11.68 M
|
$11.55 M
|
$11.45 M
|
$11.37 M
|
$10.94 M
|
| Weighted Average Shares
Out Diluted |
$18.19 M
|
$16.26 M
|
$12.60 M
|
$11.96 M
|
$12.04 M
|
$11.77 M
|
$11.55 M
|
$11.57 M
|
$11.56 M
|
$11.05 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
